NCT04989153

Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

China Health Promotion Foundation/the Second Affiliated Hospital of Zhejiang University, School of Medicine

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 5,000 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 25 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China.

Detailed description

Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China. We operated a multicenter cross-sectional study of subjects who underwent health checkup at nine International Healthcare Centers in China. All participants underwent gastroscopy and pathological examination, serum PG, 13C-urea breath test, and/or Hp serological current infection marker rapid test, all on the same day. PG related parameters were analyzed in different Hp subgroups and regions.

Conditions

• Gastric Cancer
• Precancerous Lesion
• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	pepsinogen	serum pepsinogen diagnosed gastric cancer and precanceous lesion

Timeline

• Start date: 2016-03-05
• Primary completion: 2022-12-31
• Completion: 2023-12-06
• First posted: 2021-08-04
• Last updated: 2021-08-04

Locations

9 sites across 1 country: China